Merck's $9.2 billion acquisition of Cidara Therapeutics aims to bolster its antiviral portfolio ahead of the Keytruda patent expiration. This strategic purchase signals a broader investment opportunity in biotech firms with advanced clinical assets, positioning them as attractive targets for major pharmaceutical companies.
Published on November 15
Merck's $9.2 billion Cidara acquisition signals a new wave of biotech M&A activity. Other pharmaceutical giants are likely to follow suit, creating multiple opportunities for strategic deals.
Major pharmaceutical companies face billions in revenue losses from expiring patents. This urgency is driving aggressive acquisition strategies to replenish their drug pipelines.
The high valuation paid for Cidara demonstrates that companies with late-stage clinical assets can command significant premiums, benefiting shareholders of potential targets.
Large pharmaceutical companies are facing significant revenue declines from expiring patents on blockbuster drugs like Keytruda. To secure future growth, these giants are increasingly acquiring smaller biotechnology firms with innovative, late-stage clinical assets. This creates a compelling two-sided investment opportunity in both the acquirers and potential targets.
This group captures both major pharmaceutical players with the capital to make strategic purchases and smaller biotech companies whose promising drug candidates could make them prime acquisition targets. The recent Merck-Cidara deal at $9.2 billion demonstrates the high valuations being paid for advanced clinical assets.
These stocks were handpicked by professional analysts based on their strategic positioning in the biotech M&A landscape. The selection includes established pharmaceutical giants actively seeking acquisitions and innovative biotech firms with late-stage clinical programmes that could attract takeover interest from larger players.
This basket's total market capitalisation is 2,041,697.1574, and a small number of very large-cap stocks anchor its value, giving it a relatively stable profile.
MRK: $230.63B
PFE: $142.48B
BMY: $94.97B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+7
Here are a few of the assets in this group. Create an account to unlock the full list.
On average, analysts expect assets in this group to grow 15.53% over the next year.
12 of 15 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+15.53%
